Richard O'Brien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Richard O'Brien has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Andrew Ramsay
1 shared publication- Barnabas Nyesiga
FIND, Foundation for Innovative New Diagnostics, Kampala, Uganda
1 shared publication - Dick van Soolingen
Tuberculosis Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
1 shared publication - Dinh N Sy
National Lung Hospital, 463 Hoang Hoa Tham, Ba Dinh district, Ha Noi, Viet Nam
1 shared publication - Edine W. Tiemersma
KNCV Tuberculosis Foundation, The Hague, the Netherlands
1 shared publication - Frank Gj Cobelens
Department of Global Health and Amsterdam Institute for Global Health and Development, Academic Medical Center, Amsterdam, Netherlands.
1 shared publication
Latest Publications
- Open Access
- 3 June 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 149
Validation of the GenoType®MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam
Background: To control multidrug resistant tuberculosis (MDR-TB), the drug susceptibility profile is needed to guide therapy. Classical drug susceptibility testing (DST) may take up to 2 to 4 months. The GenoType® MTBDRplus test is a commercially available line-probe assay that rapidly detects Mycobacterium tuberculosis (MTB) complex, as well as the most common mutations associated with rifampin and isoniazid resistance. We assessed sensitivity and specificity of the assay by using a geographically representative set of MTB isolates from the South of Vietnam. Methods: We re-cultured 111 MTB isolates that were MDR, rifampin-resistant or pan-susceptible according to conventional DST and tested these with the GenoType® MTBDRplus test. Results: By conventional DST, 55 strains were classified as MDR-TB, four strains were rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs. The sensitivity of the GenoType® MTBDRplus was 93.1% for rifampicin, 92.6% for isoniazid and 88.9% for the combination of both; its specificity was 100%. The positive predictive value of the GenoType® MTBDRplus test for MDR-TB was 100% and the negative predictive value 90.3%. Conclusions: We found a high specificity and positive predictive value of the GenoType® MTBDRplus test for MDR-TB which merits its use in the MDR-TB treatment program in Vietnam.
- 3 June 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 149
Open AccessValidation of the GenoType®MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam
Background: To control multidrug resistant tuberculosis (MDR-TB), the drug susceptibility profile is needed to guide therapy. Classical drug susceptibility testing (DST) may take up to 2 to 4 months. The GenoType® MTBDRplus test is a commercially available line-probe assay that rapidly detects Mycobacterium tuberculosis (MTB) complex, as well as the most common mutations associated with rifampin and isoniazid resistance. We assessed sensitivity and specificity of the assay by using a geographically representative set of MTB isolates from the South of Vietnam. Methods: We re-cultured 111 MTB isolates that were MDR, rifampin-resistant or pan-susceptible according to conventional DST and tested these with the GenoType® MTBDRplus test. Results: By conventional DST, 55 strains were classified as MDR-TB, four strains were rifampicin mono-resistant and 52 strains were susceptible to all first-line drugs. The sensitivity of the GenoType® MTBDRplus was 93.1% for rifampicin, 92.6% for isoniazid and 88.9% for the combination of both; its specificity was 100%. The positive predictive value of the GenoType® MTBDRplus test for MDR-TB was 100% and the negative predictive value 90.3%. Conclusions: We found a high specificity and positive predictive value of the GenoType® MTBDRplus test for MDR-TB which merits its use in the MDR-TB treatment program in Vietnam.
- Open Access
- 26 February 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 41
Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda
About 500 new smear-positive Multidrug-resistant tuberculosis (MDR-TB) cases are estimated to occur per year in Uganda. In 2008 in Kampala, MDR-TB prevalence was reported as 1.0% and 12.3% in new and previously treated TB cases respectively. Line probe assays (LPAs) have been recently approved for use in low income settings and can be used to screen smear-positive sputum specimens for resistance to rifampicin and isoniazid in 1-2 days.
- 26 February 2010
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 10 (1) , 41
Open AccessRapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda
About 500 new smear-positive Multidrug-resistant tuberculosis (MDR-TB) cases are estimated to occur per year in Uganda. In 2008 in Kampala, MDR-TB prevalence was reported as 1.0% and 12.3% in new and previously treated TB cases respectively. Line probe assays (LPAs) have been recently approved for use in low income settings and can be used to screen smear-positive sputum specimens for resistance to rifampicin and isoniazid in 1-2 days.
- 1 October 2009
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 9 (7) , 637-639
Comprehensive new resource for evidence-based TB diagnosis
- 1 October 2009
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 9 (7) , 637-639
Comprehensive new resource for evidence-based TB diagnosis